| Issue | Title | |
| Vol 2013, No 7 (2013) | Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 60 (2005) | AVANIR Pharmaceuticals Lands Research Deal with Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | AVANT and Celldex in Reverse Merger | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | Aventis and ImmunoGen Enter Anticancer Antibody Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 40 (2003) | Aventis and Regeneron Enter Collaboration for VEGF Trap | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 48 (2004) | Aventis Finally Succumbs to Sanofi-Synthelabo's Advances | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | Aventis to co-market Genta’s Genasense™ | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 6 (2011) | AVEO Licenses Early-Stage RON-Targeted Antibodies to Centocor Ortho Biotech | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 9 (2015) | Aveo Looks to Brighter Future with Novartis Licensing Deal | Abstract html |
| Heather Cartwright & Tridisha Goswami | ||
| Vol 2007, No 83 (2007) | AVEO Pharmaceuticals and AstraZeneca: A Platform for Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Avexa Ltd | Abstract |
| Business Review Editor | ||
| Vol 2006, No 70 (2006) | Avidex Ltd | Abstract |
| Business Review Editor | ||
| Vol 2022, No 8 (2022) | Avista Therapeutics Signs Gene Therapy Partnership with Roche for US$1 B | Abstract pdf html |
| Neha Madhwani | ||
| Vol 2010, No 10 (2010) | Axcan Offers to Acquire Eurand to Accelerate its Speciality Pharma Business | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 24 (2002) | AxCell in collaboration with Mount Sinai School of Medicine | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 7 (2018) | Axovant Focuses on Gene Therapy with Benitec Partnership | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 63 (2005) | Baltic States Bring Biotech Expertise to Enlarged Europe | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 74 (2006) | Barr and Actavis Battle for PLIVA | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 41 (2003) | Barr and Galen Trade Rights for Women’s Health Products | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 12 (2012) | BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 11 (2023) | Basilea Pays US$37 M Upfront for Antifungal from Pfizer’s Amplyx | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2005, No 57 (2005) | Basilea’s Deal Making Debut | Abstract |
| Business Review Editor | ||
| Vol 2012, No 4 (2012) | Bausch & Lomb Tops Valeant with US$500 M Bid for ISTA | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 12 (2018) | Bausch Health Acquires Synergy Pharmaceuticals for US$200 M | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 63 (2005) | Bavarian Nordic AS | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 1 (2012) | Baxter and Momenta Form Global Collaboration to Develop and Commercialise Biosimilars | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 2 (2013) | Baxter Buys Late-Stage Haemophilia Drug OBI-1 from Ipsen and Troubled Inspiration Biopharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 9 (2011) | Baxter Expands its Medication Delivery Business with Baxa Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 9 (2012) | Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 4 (2014) | Baxter Follows Abbott’s Lead with Plan to Split into Two Independent Companies | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 6 (2012) | Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 5 (2014) | Baxter Strengthens Haemophilia Franchise with Chatham Therapeutics Purchase as Biogen Enters Market | Abstract Untitled |
| Heather Cartwright | ||
| Vol 2016, No 3 (2016) | Baxter’s Foray Into CAR-T Cell Therapy With a Deal Worth US$ 1.7 B | Abstract pdf html |
| Taskin Ahmed & Rohit Khera | ||
| Vol 2009, No 4 (2009) | Bayer and Ardea in Cancer Drug Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 10 (2012) | Bayer and Evotec Collaborate to Develop Three Endometriosis Drug Candidates | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 87 (2007) | Bayer and Nektar Collaborate on Inhaled Pneumonia Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2015, No 5 (2015) | Bayer Augments Thrombosis Pipeline by Licensing ISIS-FXIRx from Isis Pharmaceuticals | Abstract pdf |
| Heather Cartwright & Rohit Khera | ||
| Vol 2006, No 71 (2006) | Bayer Bids for Successful Schering | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 11 (2017) | Bayer Bolsters Pipeline with Two US$1 Billion Dollar Deals | Abstract pdf html |
| Natasha Piper | ||
| Vol 2013, No 5 (2013) | Bayer Boosts Contraceptive Business with US$1.1 B Conceptus Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 37 (2003) | Bayer Buys Marketing Rights to GW Pharmaceuticals’ Cannabis-Based Treatment | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 8 (2013) | Bayer Expands Research in Cancer Immunotherapy with Compugen Pact | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 66 (2005) | Bayer Helps J&J Expand Cardiology Franchise | Abstract |
| Business Review Editor | ||
| Vol 2020, No 12 (2020) | Bayer Highlights Cell and Gene Therapy Commitment with US$4 B Asklepios Buyout | Abstract pdf html |
| Ashish Tripathi & Michelle Liu | ||
| Vol 2019, No 6 (2019) | Bayer Latest to Join Protein Degrader Space with Arvinas Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 8 (2011) | Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 2 (2021) | Bayer Partners with Atara Therapeutics for Mesothelin-directed CAR-T Therapies | Abstract pdf html |
| Shikha Kashyap & Michelle Liu | ||
| Vol 2014, No 8 (2014) | Bayer Returns to Gene Therapy Arena with Dimension Therapeutics Deal | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 80 (2007) | Bayer Schering Pharma Builds on Core Schering Technology in Neurodegenerative Diseases | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 9 (2009) | Bayer Signs Global Agreement for Alpharadin with Algeta | Abstract |
| Taskin Ahmed | ||
| Vol 2023, No 5 (2023) | Bayer Signs US$1.7 B Deal with Bicycle Therapeutics for Cancer Radiopharmaceuticals | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2012, No 11 (2012) | Bayer Spin-Off AiCuris Licenses Phase III-Ready Antiviral to Merck & Co. | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 9 (2021) | Bayer Strengthens Drug Discovery Platform with US$2 B Vividion Buyout | Abstract pdf html |
| Debadrita Paul | ||
| Vol 2019, No 8 (2019) | Bayer to Build Cell Therapy Pipeline with BlueRock Therapeutics Acquisition | Abstract html pdf |
| Michelle Liu | ||
| Vol 2014, No 5 (2014) | Bayer Wins Auction for Merck & Co.’s OTC Business and Offers Cardiovascular Disease Collaboration Sweetener | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 55 (2005) | Bayer: Seeking Reformulation | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 100 (2008) | Bayer’s Foray into Biotech | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2022, No 10 (2022) | Bayer’s Vividion Signs US$930 M Cancer Collaboration with Tavros Therapeutics | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2005, No 65 (2005) | Be Quick, be Brave, be Successful | Details html |
| Fintan Walton | ||
| Vol 2017, No 5 (2017) | Becton Dickinson Acquires Fellow Medtech Bard for Massive US$24 B | Abstract pdf html |
| Natasha Piper | ||
| Vol 2012, No 1 (2012) | Benchmarking – A Market Approach to Valuation | Abstract |
| Nigel Borshell | ||
| Vol 2002, No 25 (2002) | Berna Biotech acquires Rhein Biotech for US$257 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 3 (2020) | Bicycle Signs US$1.7 B Immuno-oncology Collaboration with Genentech | Abstract html pdf |
| Michelle Liu | ||
| Vol 2008, No 94 (2008) | Bifeprunox | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 80 (2007) | Big Pharma | Details jpg |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Big Pharma and the Young CEO | Abstract html |
| Fintan Walton | ||
| Vol 2002, No 28 (2002) | Big Pharma Mergers | Abstract |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Big Pharma Product Divestments– Buying the Cast-Offs | Abstract |
| Business Review Editor | ||
| Vol 2008, No 91 (2008) | Big Pharma Strategies for Biologics Catch-Up | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 101 (2008) | Bio-Diversity | Abstract html |
| Fintan Walton | ||
| Vol 2014, No 5 (2014) | BioAlliance Pharma and Topotarget Agree to Merge and Combine Late-State Orphan Oncology Assets | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 3 (2022) | Biocon Biologics Acquires Viatris’ Biosimilar Portfolio for US$3.3 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 2 (2013) | Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 11 (2012) | BioCryst and Presidio Merge to Compete in Oral Hepatitis C Drug Development | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 69 (2006) | BioCryst Collaborates in Oncology with Mundipharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | BioCryst: The Fall and Rise of Peramivir | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Bioenvision | Abstract |
| Business Review Editor | ||
| Vol 2009, No 8 (2009) | Biogen Acquires Rights to Multiple Sclerosis Pill | Abstract |
| Taskin Ahmed | ||
| Vol 2020, No 2 (2020) | Biogen Adds Pfizer’s PF-05251749 to its Neuroscience Pipeline in US$710 M Deal | Abstract html pdf |
| Neha Madhwani | ||
| Vol 2005, No 58 (2005) | Biogen and Elan Lose Market Value as Tysabri® Withdrawn | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 2 (2022) | Biogen Bets US$30 M on Genentech’s Lymphoma Bispecific Antibody | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 1 (2019) | Biogen Bolsters Neurology Pipeline with C4 Therapeutics and Skyhawk Deals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2003, No 38 (2003) | Biogen Follows Patent Licensing with Genentech Research Agreement | Abstract |
| Business Review Editor | ||
| Vol 2025, No 3 (2025) | Biogen Gains Rights to Stoke Therapeutics’ Zorevunersen for the Treatment of Dravet Syndrome | Abstract pdf html |
| Naini Anand | ||
| Vol 2012, No 7 (2012) | Biogen Idec and Isis Pharmaceuticals Sign Second Rare Disease Option Agreement | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 9 (2011) | Biogen Idec and Novo Nordisk Join Adimab’s List of Antibody Discovery Partners | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 63 (2005) | Biogen Idec and PDL: Licensing Triumphs over Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 11 (2011) | Biogen Idec and Portola Pharmaceuticals Collaborate on Oral Syk Inhibitors for Autoimmune Diseases | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 52 (2004) | Biogen Idec and Sunesis Sign Small Molecule Cancer Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 2 (2013) | Biogen Idec Buys Complete Ownership of Tysabri® from Elan | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 12 (2101) | Biogen Idec Enters Biosimilars Market via Joint Venture with Samsung Biologics | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 2 (2014) | Biogen Idec Enters Genome-Editing Field with Sangamo BioSciences Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 1 (2011) | Biogen Idec Expands its Neurology Pipeline by Acquiring Three Programmes from Neurimmune | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Biogen Idec Expands its Portfolio with ALS Drug Candidate | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 1 (2012) | Biogen Idec Options Isis Pharmaceuticals’ Antisense Drug for Spinal Muscular Atrophy | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 2 (2012) | Biogen Idec Retrieves its Idiopathic Pulmonary Fibrosis Drug via US$562.5 M Stromedix Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 12 (2012) | Biogen Idec Signs Third Antisense Deal of 2012 with Isis Pharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 32 (2003) | Biogen in Research Alliance with Sunesis | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 3 (2019) | Biogen Jumps on Gene Therapy Train with Nightstar Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 8 (2021) | Biogen Licenses InnoCare’s Orelabrutinib to Strengthen Multiple Sclerosis Presence | Abstract pdf html |
| Debadrita Paul | ||
| 601 - 700 of 2581 Items | << < 2 3 4 5 6 7 8 9 10 11 > >> | |